[1] Chen N,Zhou M,Dong X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study.The Lancet,2020,395:391-393.
[2] 中华医学会,中华中医药学会.传染性非典型肺炎(SARS)诊疗方案(续).现代实用医学,2004,16:172-183.
[3] Guan WJ,Ni ZY,Hu Y,et al.Clinical characteristics of 2019 novel coronavirus infection in China.MedRxiv,2020.
[4] Tisoncik JR,Korth MJ,Simmons CP,et al.Into the eye of the cytokine storm.Microbiol,Mol Biol Rev,2012,76:16-32.
[5] Chen J,Subbarao K,The immunobiology of SARS,Annu Rev Immunol,2007,25:443-472.
[6] 段钟平,陈煜,张晶,等.严重急性呼吸道综合征并发肝脏损害的临床特点与机制探讨.中华肝脏病杂志,2003,11:493-496.
[7] Chai X,Hu L,Zhang Y,et al.Specific ACE2 expression in cholangiocytes maycauser liver damage after 2019-ncov infection.bioRxiv,(2020-2-15)[2020-1-13],http://www.instrument.com/cn/download/shtml/932534.shtml
[8] Zhao Y,Zhao Z,Wang Y,et al.Single-cell RNA expression profiling of ACE2,the putative receptor of 2019-nCoV.BioRxiv,2020.
[9] 陈丹龙,杨芳,罗志英,等.全球抗新冠病毒药物研发现状和瓶颈.中国药理学通报,2020,36:1-11. |
